Skip to main content
. Author manuscript; available in PMC: 2022 Jul 15.
Published in final edited form as: Clin Cancer Res. 2021 Nov 2;28(2):414–424. doi: 10.1158/1078-0432.CCR-21-1535

Figure 3. Cholesterol-lowering increases CD8+ T cell memory and enhances recalled response.

Figure 3.

A. Pmel-1 lymphocytes were adoptive transferred into congenic mice followed by ezetimibe treatment. Mice were injected with DCs pulsed with gp100 peptide on day 0 and day 20 (DC vaccination). Representative results are shown for triplicate experiments with 4-6 mice per experimental group. B-C. Lymphocytes were harvest on day 10 and analyzed for the indicated markers by flow cytometry. B. Donor Pmel-1 lymphocytes (Thy1.1+) were increased in ezetimibe-treated animals following DC vaccination and all CD8+ lymphocytes displayed a memory phenotype with increase in CD62L and CD44 expressing. C. CPT1A staining intensity was assessed in CD8+Thy1.1+ and CD8+Thy1.1− cells. D-F. Mice were restimulated with DC vaccination on day 20 and lymphocytes were harvested 3 days later. D. Ezetimibe treatment was associated with a greater recall proliferation of Pmel-1 CD8+ lymphocytes, which displayed a memory phenotype with increase in CD62L and CD44 expression. E-F. PD1 and Granzyme B expressions were assessed in CD8+Thy1.1+ and CD8+Thy1.1− cells. Error bars represent standard error.